Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2014-09-25

Clinical Trial Update: A Study Of CP-195543 And Celecoxib Dual Therapy In Subjects With Rheumatoid Arthritis [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating dual therapy with CP-195543 and celecoxib in rheumatoid arthritis was terminated, and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • CP-195543 (CP-195543)
  • Celecoxib (Celecoxib)

Snippet

Sponsor: Pfizer | Conditions: Arthritis, Rheumatoid | Phase 2 | Status: TERMINATED | Results posted: 2014-09-25